

**Thrombocytopenia Working Group**  
**Berlin, 14 th congress of EHA, June 4<sup>th</sup> 2009**  
**Report of the meeting**

This meeting was the last one chaired by **Bertrand Godeau** (Créteil, France). The future chairwoman for the next three years will be **Doctor Nichola Cooper** (London, UK) with the agreement of all the members of the Working group. The past chairman and Francesco Rodeghiero warmly acknowledged Doctor Cooper to accept this function.

During the meeting, **James Bussel (New York, USA)** reviewed the data focused *on fatigue and quality of life in ITP*. A prospective study could be activated in the next future to determine the incidence and the mechanism of the fatigue in adult ITP.

**Marco Ruggeri** (Vincenza, Italy) reviewed the data available in the literature focused on *thrombosis and ITP* (incidence, pathophysiology). This topic appears particularly important with the recent development of thrombopoietic agents. An international study conducted by Marco Ruggeri and Francesco Rodeghiero is planned with the aim to determine its incidence and mechanism.

**Marc Michel (Créteil, France)** reviewed the data of literature and emphasized the need of developing a validated tool to assess *bleeding score in children and adult's ITP*. An international collaborative study is planned with the aim to develop a simple, consensual and reproducible bleeding score.

Due to the absence of **Drew Provan (London, UK)** who could not attend the meeting, **Bertrand Godeau** presented the preliminary conclusions of the International cooperative group concerning an update on *diagnosis and treatment of ITP*. This presentation was only focused on the adult form of the disease and did not review the pediatric aspects nor ITP during pregnancy. The conclusions of this collaborative study are submitted for publication.

**Nichola Cooper (London, UK)** reviewed the data available in the literature regarding the risk of *progressive multifocal leukoencephalopathy (PML) in autoimmune diseases* in patients treated with rituximab and particularly ITP. To date, a single case of PML has been reported in an ITP patient. An international registry has been proposed to estimate the real incidence of this very rare although life-threatening opportunistic infection.

Finally, Bertrand Godeau warmly acknowledged all the members of the thrombocytopenia WG for their implication during the past three years with a special thank for Francesco Rodeghiero, Marco Ruggeri and Marc Michel for their help. Bertrand Godeau also acknowledged all colleagues from Europe but also from non-European countries who did actively participate to the meetings, for their input and the interesting discussions we had during the last three years.